Trials (Kortrijk Cancer Centre AZ Groeninge) - Revision history

Francine: /* Trials: How to access */

2025-12-14T14:10:15Z

Trials: How to access

← Older revision		Revision as of 14:10, 14 December 2025
Line 7:		Line 7:
	Go back to [[Kortrijk Cancer Centre AZ Groeninge]] page		Go back to [[Kortrijk Cancer Centre AZ Groeninge]] page

	=== Trials: How to ~~access~~ ===		=== Trials: How to participate ===
	'''Contact information:''' [https://www.azgroeninge.be/nl/patient/over-az-groeninge/klinische-studies Click here to access].		'''Contact information:''' [https://www.azgroeninge.be/nl/patient/over-az-groeninge/klinische-studies Click here to access].

Francine at 13:14, 14 December 2025

2025-12-14T13:14:40Z

← Older revision		Revision as of 13:14, 14 December 2025
Line 9:		Line 9:
	=== Trials: How to access ===		=== Trials: How to access ===
	'''Contact information:''' [https://www.azgroeninge.be/nl/patient/over-az-groeninge/klinische-studies Click here to access].		'''Contact information:''' [https://www.azgroeninge.be/nl/patient/over-az-groeninge/klinische-studies Click here to access].


	'''NCTID''': NCT01332968		'''NCTID''': NCT01332968

Francine at 13:14, 14 December 2025

2025-12-14T13:14:25Z

← Older revision		Revision as of 13:14, 14 December 2025
Line 6:		Line 6:
	<span style="display:none">cancer center</span>		<span style="display:none">cancer center</span>
	Go back to [[Kortrijk Cancer Centre AZ Groeninge]] page		Go back to [[Kortrijk Cancer Centre AZ Groeninge]] page

			=== Trials: How to access ===
			'''Contact information:''' [https://www.azgroeninge.be/nl/patient/over-az-groeninge/klinische-studies Click here to access].

	'''NCTID''': NCT01332968		'''NCTID''': NCT01332968
Line 82:		Line 85:
	<span style="display:none">hasCancerType::D37-D48: Growths of uncertain nature</span>		<span style="display:none">hasCancerType::D37-D48: Growths of uncertain nature</span>
	<span style="display:none">hasCancerType::unknown</span>		<span style="display:none">hasCancerType::unknown</span>
			<span style="display:none">isTrial</span>

Lucas: Update categories.

2025-12-06T12:41:54Z

Update categories.

← Older revision		Revision as of 12:41, 6 December 2025
Line 61:		Line 61:
	'''Recruitment Status''': TERMINATED		'''Recruitment Status''': TERMINATED
	'''Condition''': Prostate Cancer		'''Condition''': Prostate Cancer
			<span style="display:none">hasCancerType::C00-D48: All neoplasms</span>
			<span style="display:none">hasCancerType::C00-C97: All cancer types</span>
			<span style="display:none">hasCancerType::C00-C14: Mouth/throat cancers</span>
			<span style="display:none">hasCancerType::C15-C26: Digestive system cancers</span>
			<span style="display:none">hasCancerType::C30-C39: Lung/chest cancers</span>
			<span style="display:none">hasCancerType::C40-C41: Bone cancers</span>
			<span style="display:none">hasCancerType::C43-C44: Skin cancers/melanoma</span>
			<span style="display:none">hasCancerType::C45-C49: Soft tissue cancer</span>
			<span style="display:none">hasCancerType::C50: Breast cancer</span>
			<span style="display:none">hasCancerType::C51-C58: Female genitalia cancers</span>
			<span style="display:none">hasCancerType::C60-C63: Male genitalia cancer</span>
			<span style="display:none">hasCancerType::C64-C68: Urinary system cancers</span>
			<span style="display:none">hasCancerType::C69-C72: Eye and brain cancer</span>
			<span style="display:none">hasCancerType::C73-C75: Thyroid and other gland cancers</span>
			<span style="display:none">hasCancerType::C76-C80: Cancers of unknown or unspecified areas</span>
			<span style="display:none">hasCancerType::C81-C96: Cancers of the blood and immune system</span>
			<span style="display:none">hasCancerType::C97-C97: Cancers in multiple locations from the start</span>
			<span style="display:none">hasCancerType::D00-D09: Early-stage cancers not yet spread</span>
			<span style="display:none">hasCancerType::D10-D36: Benign tumour</span>
			<span style="display:none">hasCancerType::D37-D48: Growths of uncertain nature</span>
			<span style="display:none">hasCancerType::unknown</span>

Lucas: Update categories.

2025-12-02T13:59:50Z

Update categories.

← Older revision		Revision as of 13:59, 2 December 2025
Line 1:		Line 1:
	{{forpatients}}		<span style="display:none">forpatients</span>
	{{forproviders}}		<span style="display:none">forproviders</span>
	{{forresearchers}}		<span style="display:none">forresearchers</span>
	{{belgiumcountry}}		<span style="display:none">belgiumcountry</span>
	{{hospital}}		<span style="display:none">hospital</span>
	{{cancer center}}		<span style="display:none">cancer center</span>
	Go back to [[Kortrijk Cancer Centre AZ Groeninge]] page		Go back to [[Kortrijk Cancer Centre AZ Groeninge]] page

Francine at 11:40, 2 December 2025

2025-12-02T11:40:53Z

← Older revision		Revision as of 11:40, 2 December 2025
Line 2:		Line 2:
	{{forproviders}}		{{forproviders}}
	{{forresearchers}}		{{forresearchers}}
	{{~~belgium~~}}		{{belgiumcountry}}
	{{hospital}}		{{hospital}}
	{{cancer center}}		{{cancer center}}

Victor at 18:12, 6 November 2024

2024-11-06T18:12:52Z

← Older revision		Revision as of 18:12, 6 November 2024
Line 3:		Line 3:
	{{forresearchers}}		{{forresearchers}}
	{{belgium}}		{{belgium}}
			{{hospital}}
			{{cancer center}}
	Go back to [[Kortrijk Cancer Centre AZ Groeninge]] page		Go back to [[Kortrijk Cancer Centre AZ Groeninge]] page

Victor at 16:50, 5 November 2024

2024-11-05T16:50:28Z

← Older revision		Revision as of 16:50, 5 November 2024
Line 2:		Line 2:
	{{forproviders}}		{{forproviders}}
	{{forresearchers}}		{{forresearchers}}
			{{belgium}}

	Go back to [[Kortrijk Cancer Centre AZ Groeninge]] page		Go back to [[Kortrijk Cancer Centre AZ Groeninge]] page

Francine at 13:05, 2 May 2024

2024-05-02T13:05:32Z

← Older revision		Revision as of 13:05, 2 May 2024
Line 6:		Line 6:

	'''NCTID''': NCT01332968		'''NCTID''': NCT01332968
	'''Title'''~~: [[hasTrialTitle:~~:A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)]]		'''Title''': A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
	'''Study Summary''': This open-label, randomized study will assess the efficacy and safety of obinutuzumab (RO5072759) in combination with chemotherapy compared to rituximab (MabThera/Rituxan) with chemotherapy followed by obinutuzumab or rituximab maintenance in participants with untreated advanced indolent non-Hodgkin's lymphoma. After the end of the induction period, participants achieving response (Complete response \[CR\] or partial response \[PR\]) will undergo a maintenance period continuing on the randomized antibody treatment alone every 2 months until disease progression for a total of 2 years. Anticipated time on study treatment is up to approximately 2.5 years. After maintenance or observation, participants will be followed for 5 years until progression. After progression, participants will be followed for new anti-lymphoma therapy and overall survival until the end of the study.		'''Study Summary''': This open-label, randomized study will assess the efficacy and safety of obinutuzumab (RO5072759) in combination with chemotherapy compared to rituximab (MabThera/Rituxan) with chemotherapy followed by obinutuzumab or rituximab maintenance in participants with untreated advanced indolent non-Hodgkin's lymphoma. After the end of the induction period, participants achieving response (Complete response \[CR\] or partial response \[PR\]) will undergo a maintenance period continuing on the randomized antibody treatment alone every 2 months until disease progression for a total of 2 years. Anticipated time on study treatment is up to approximately 2.5 years. After maintenance or observation, participants will be followed for 5 years until progression. After progression, participants will be followed for new anti-lymphoma therapy and overall survival until the end of the study.
	'''Sponsor''': Hoffmann-La Roche		'''Sponsor''': Hoffmann-La Roche
Line 17:		Line 17:

	'''NCTID''': NCT00774345		'''NCTID''': NCT00774345
	'''Title'''~~: [[hasTrialTitle:~~:A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy]]		'''Title''': A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy
	'''Study Summary''': The purpose of this study is to determine if lenalidomide (Revlimid®) is safe and effective as a maintenance therapy at improving further the quality of the response you achieved with your last therapy and at prolonging the duration of your response. This study will compare the effects (good and bad) of lenalidomide with the dummy drug.		'''Study Summary''': The purpose of this study is to determine if lenalidomide (Revlimid®) is safe and effective as a maintenance therapy at improving further the quality of the response you achieved with your last therapy and at prolonging the duration of your response. This study will compare the effects (good and bad) of lenalidomide with the dummy drug.
	'''Sponsor''': Celgene		'''Sponsor''': Celgene
Line 28:		Line 28:

	'''NCTID''': NCT04987203		'''NCTID''': NCT04987203
	'''Title'''~~: [[hasTrialTitle:~~:Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma]]		'''Title''': Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
	'''Study Summary''': This study will be comparing tivozanib in combination with nivolumab to tivozanib alone in subjects with advanced Renal Cell Carcinoma (RCC) who have had 1 or 2 prior lines of therapy, one of which was an Immune Checkpoint Inhibitor (ICI).		'''Study Summary''': This study will be comparing tivozanib in combination with nivolumab to tivozanib alone in subjects with advanced Renal Cell Carcinoma (RCC) who have had 1 or 2 prior lines of therapy, one of which was an Immune Checkpoint Inhibitor (ICI).
	'''Sponsor''': AVEO Pharmaceuticals, Inc.		'''Sponsor''': AVEO Pharmaceuticals, Inc.
Line 39:		Line 39:

	'''NCTID''': NCT05947903		'''NCTID''': NCT05947903
	'''Title'''~~: [[hasTrialTitle:~~:Validation of the European Oncology Quality of Life Toolkit]]		'''Title''': Validation of the European Oncology Quality of Life Toolkit
	'''Study Summary''': The improvement or preservation of quality of life (QoL) is one of the three pillars of the European Union (EU) Mission on Cancer, which underpins the needs of patients from cancer diagnosis throughout treatment, survivorship, and advanced terminal stages. Clinical studies and real-world data show that the use of Patient Reported Outcome Measures (PROMs) for QoL assessment in routine oncology practice has positive effects on patient wellbeing and healthcare resource utilization. However, full implementation of PROMs is not yet part of standard of care and is not adequately considered in cancer policies and programs.A comprehensive tool incorporating the perspective of patients at different stages of the disease trajectory and widely applicable across Europe is still lacking.The European Oncology Quality of Life Toolkit (EUonQoL-Kit) is a unified patient-centred tool for the assessment of QoL, developed from preferences and priorities of people with past or current cancer experience. The EUonQoL-Kit includes three electronic questionnaires, specifically designed for different disease phases (patients in active treatment, survivors, and patients in palliative care), available in both static and dynamic (Computer Adaptive Testing, CAT) versions and in several European languages. This is a multicentre observational study, with the following aims:* The primary aim is to perform the psychometric validation of the EUonQoL-Kit.* Secondary aims are to assess its acceptability, to validate the CAT version, and to provide estimates of QoL across different European countries. The EUonQoL-Kit will be administered to a sample of cancer patients and survivors from 46 European cancer centres. The sample will include patients in active treatment (group A), survivors (group B), and patients in Palliative Care (group C). Each centre will recruit 100 patients (40 from group A, 30 from group B, 30 from group C), for an overall sample size of 4,600 patients (at least 4,000 patients are assumed to be enrolled, due to an expected lower recruitment rate of 10-15%). Three sub-samples of patients (each corresponding to 10% of the total sample for each centre) will fill in an additional questionnaire:* EORTC QLQ-C30, to test concurrent validity.* Live-CAT version, to test the feasibility of such implementation.* EUonQoL-Kit, 2-7 days after the first completion, to assess test-retest reliability.		'''Study Summary''': The improvement or preservation of quality of life (QoL) is one of the three pillars of the European Union (EU) Mission on Cancer, which underpins the needs of patients from cancer diagnosis throughout treatment, survivorship, and advanced terminal stages. Clinical studies and real-world data show that the use of Patient Reported Outcome Measures (PROMs) for QoL assessment in routine oncology practice has positive effects on patient wellbeing and healthcare resource utilization. However, full implementation of PROMs is not yet part of standard of care and is not adequately considered in cancer policies and programs.A comprehensive tool incorporating the perspective of patients at different stages of the disease trajectory and widely applicable across Europe is still lacking.The European Oncology Quality of Life Toolkit (EUonQoL-Kit) is a unified patient-centred tool for the assessment of QoL, developed from preferences and priorities of people with past or current cancer experience. The EUonQoL-Kit includes three electronic questionnaires, specifically designed for different disease phases (patients in active treatment, survivors, and patients in palliative care), available in both static and dynamic (Computer Adaptive Testing, CAT) versions and in several European languages. This is a multicentre observational study, with the following aims:* The primary aim is to perform the psychometric validation of the EUonQoL-Kit.* Secondary aims are to assess its acceptability, to validate the CAT version, and to provide estimates of QoL across different European countries. The EUonQoL-Kit will be administered to a sample of cancer patients and survivors from 46 European cancer centres. The sample will include patients in active treatment (group A), survivors (group B), and patients in Palliative Care (group C). Each centre will recruit 100 patients (40 from group A, 30 from group B, 30 from group C), for an overall sample size of 4,600 patients (at least 4,000 patients are assumed to be enrolled, due to an expected lower recruitment rate of 10-15%). Three sub-samples of patients (each corresponding to 10% of the total sample for each centre) will fill in an additional questionnaire:* EORTC QLQ-C30, to test concurrent validity.* Live-CAT version, to test the feasibility of such implementation.* EUonQoL-Kit, 2-7 days after the first completion, to assess test-retest reliability.
	'''Sponsor''': Fondazione IRCCS Istituto Nazionale dei Tumori, Milano		'''Sponsor''': Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Line 50:		Line 50:

	'''NCTID''': NCT00089856		'''NCTID''': NCT00089856
	'''Title'''~~: [[hasTrialTitle:~~:GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer]]		'''Title''': GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer
	'''Study Summary''': The purpose of this study is to compare the duration of survival between GVAX® immunotherapy for prostate cancer and chemotherapy treatment in patients with prostate cancer who no longer respond to hormone therapy, who have documented metastases, and who have not been treated with chemotherapy in the past.		'''Study Summary''': The purpose of this study is to compare the duration of survival between GVAX® immunotherapy for prostate cancer and chemotherapy treatment in patients with prostate cancer who no longer respond to hormone therapy, who have documented metastases, and who have not been treated with chemotherapy in the past.
	'''Sponsor''': Cell Genesys		'''Sponsor''': Cell Genesys

Francine at 13:41, 4 January 2024

2024-01-04T13:41:22Z

← Older revision		Revision as of 13:41, 4 January 2024
Line 37:		Line 37:
	'''Recruitment Status''': ACTIVE_NOT_RECRUITING		'''Recruitment Status''': ACTIVE_NOT_RECRUITING
	'''Condition''': Renal Cell Carcinoma		'''Condition''': Renal Cell Carcinoma

	'''NCTID''': NCT05947903		'''NCTID''': NCT05947903
	'''Title''': Validation of the European Oncology Quality of Life Toolkit		'''Title''': [[hasTrialTitle::Validation of the European Oncology Quality of Life Toolkit]]
	'''Study Summary''': The improvement or preservation of quality of life (QoL) is one of the three pillars of the European Union (EU) Mission on Cancer, which underpins the needs of patients from cancer diagnosis throughout treatment, survivorship, and advanced terminal stages. Clinical studies and real-world data show that the use of Patient Reported Outcome Measures (PROMs) for QoL assessment in routine oncology practice has positive effects on patient wellbeing and healthcare resource utilization. However, full implementation of PROMs is not yet part of standard of care and is not adequately considered in cancer policies and programs.A comprehensive tool incorporating the perspective of patients at different stages of the disease trajectory and widely applicable across Europe is still lacking.The European Oncology Quality of Life Toolkit (EUonQoL-Kit) is a unified patient-centred tool for the assessment of QoL, developed from preferences and priorities of people with past or current cancer experience. The EUonQoL-Kit includes three electronic questionnaires, specifically designed for different disease phases (patients in active treatment, survivors, and patients in palliative care), available in both static and dynamic (Computer Adaptive Testing, CAT) versions and in several European languages.This is a multicentre observational study, with the following aims:* The primary aim is to perform the psychometric validation of the EUonQoL-Kit.* Secondary aims are to assess its acceptability, to validate the CAT version, and to provide estimates of QoL across different European countries.The EUonQoL-Kit will be administered to a sample of cancer patients and survivors from 46 European cancer centres. The sample will include patients in active treatment (group A), survivors (group B), and patients in Palliative Care (group C).Each centre will recruit 100 patients (40 from group A, 30 from group B, 30 from group C), for an overall sample size of 4,600 patients (at least 4,000 patients are assumed to be enrolled, due to an expected lower recruitment rate of 10-15%). Three sub-samples of patients (each corresponding to 10% of the total sample for each centre) will fill in an additional questionnaire:* EORTC QLQ-C30, to test concurrent validity.* Live-CAT version, to test the feasibility of such implementation.* EUonQoL-Kit, 2-7 days after the first completion, to assess test-retest reliability.		'''Study Summary''': The improvement or preservation of quality of life (QoL) is one of the three pillars of the European Union (EU) Mission on Cancer, which underpins the needs of patients from cancer diagnosis throughout treatment, survivorship, and advanced terminal stages. Clinical studies and real-world data show that the use of Patient Reported Outcome Measures (PROMs) for QoL assessment in routine oncology practice has positive effects on patient wellbeing and healthcare resource utilization. However, full implementation of PROMs is not yet part of standard of care and is not adequately considered in cancer policies and programs.A comprehensive tool incorporating the perspective of patients at different stages of the disease trajectory and widely applicable across Europe is still lacking.The European Oncology Quality of Life Toolkit (EUonQoL-Kit) is a unified patient-centred tool for the assessment of QoL, developed from preferences and priorities of people with past or current cancer experience. The EUonQoL-Kit includes three electronic questionnaires, specifically designed for different disease phases (patients in active treatment, survivors, and patients in palliative care), available in both static and dynamic (Computer Adaptive Testing, CAT) versions and in several European languages. This is a multicentre observational study, with the following aims:* The primary aim is to perform the psychometric validation of the EUonQoL-Kit.* Secondary aims are to assess its acceptability, to validate the CAT version, and to provide estimates of QoL across different European countries. The EUonQoL-Kit will be administered to a sample of cancer patients and survivors from 46 European cancer centres. The sample will include patients in active treatment (group A), survivors (group B), and patients in Palliative Care (group C). Each centre will recruit 100 patients (40 from group A, 30 from group B, 30 from group C), for an overall sample size of 4,600 patients (at least 4,000 patients are assumed to be enrolled, due to an expected lower recruitment rate of 10-15%). Three sub-samples of patients (each corresponding to 10% of the total sample for each centre) will fill in an additional questionnaire:* EORTC QLQ-C30, to test concurrent validity.* Live-CAT version, to test the feasibility of such implementation.* EUonQoL-Kit, 2-7 days after the first completion, to assess test-retest reliability.
	'''Sponsor''': Fondazione IRCCS Istituto Nazionale dei Tumori, Milano		'''Sponsor''': Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
	'''Intervention''': Administration of the EUonQoL-Kit - Active Treatment questionnaire		'''Intervention''': Administration of the EUonQoL-Kit - Active Treatment questionnaire
Line 47:		Line 48:
	'''Recruitment Status''': NOT_YET_RECRUITING		'''Recruitment Status''': NOT_YET_RECRUITING
	'''Condition''': Cancer		'''Condition''': Cancer

	'''NCTID''': NCT00089856		'''NCTID''': NCT00089856
	'''Title''': GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer		'''Title''': [[hasTrialTitle::GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer]]
	'''Study Summary''': The purpose of this study is to compare the duration of survival between GVAX® immunotherapy for prostate cancer and chemotherapy treatment in patients with prostate cancer who no longer respond to hormone therapy, who have documented metastases, and who have not been treated with chemotherapy in the past.		'''Study Summary''': The purpose of this study is to compare the duration of survival between GVAX® immunotherapy for prostate cancer and chemotherapy treatment in patients with prostate cancer who no longer respond to hormone therapy, who have documented metastases, and who have not been treated with chemotherapy in the past.
	'''Sponsor''': Cell Genesys		'''Sponsor''': Cell Genesys